Piramal divests diagnostics arm to SRL, to retain 10% in new combine
This article was originally published in Scrip
Piramal Healthcare has divested its pathology and radiology diagnostic services subsidiary to Super Religare Laboratories (SRL) for Rs6.0 billion ($128.3 million), its second major deal in less than two months following the sale of its domestic formulations business to Abbott.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.